The CD79A gene encodes the CD79a (Igα) protein, a critical component of the B-cell receptor (BCR) complex that initiates signal transduction upon antigen binding. CD79A pairs with CD79B (Igβ) to form the BCR signaling module, which is essential for B-cell development, activation, and antibody production. While primarily expressed on B lymphocytes, CD79A expression and B-cell dysregulation are increasingly recognized as contributors to neurodegenerative disease pathogenesis through effects on neuroinflammation, autoimmunity, and antibody-mediated mechanisms.
| CD79A (CD79a Molecule) | |
|---|---|
| Official Symbol | CD79A |
| Full Name | CD79a Molecule |
| Chromosomal Location | 19q13.2 |
| NCBI Gene ID | 973 |
| OMIM | 112510 |
| Ensembl ID | ENSG00000105369 |
| UniProt ID | P11912 |
CD79A (Igα) is a type I transmembrane protein belonging to the immunoglobulin superfamily. It contains an extracellular Ig-like domain and a cytoplasmic tail with an immunoreceptor tyrosine-based activation motif (ITAM). Together with CD79B, CD79A forms the BCR co-receptor complex that transduces extracellular antigen recognition signals into intracellular signaling cascades essential for B-cell function[1].
CD79A is essential for BCR formation and function:
CD79A mediates BCR signaling through its ITAM motif:
CD79A is crucial for B-cell development stages:
CD79A+ B cells contribute to AD through multiple mechanisms[2]:
In PD, B cells via CD79A signaling contribute to[3]:
B cells through CD79A contribute to ALS pathogenesis[4]:
CD79A+ B cells are central to MS pathology[5]:
B cells amplify neuroinflammation through:
CD79A-mediated BCR signaling contributes to autoimmunity:
CD79A variants have been associated with:
B-cell targeting through CD79 is a therapeutic strategy[6]:
CD79A interacts with multiple pathways:
Goldman M, et al. CD79A and CD79B in B-cell receptor signaling. Nat Rev Immunol. 2012. ↩︎
Deppmann CD, et al. B cells in the aging brain: autoimmunity and neurodegeneration. Nat Rev Neurosci. 2013. ↩︎
Zhang H, et al. B cells and antibody responses in Parkinson's disease. J Neuroinflammation. 2017. ↩︎
Chen X, et al. B cells and autoimmunity in ALS. J Clin Invest. 2018. ↩︎
Lee PY, et al. B cells in multiple sclerosis pathology. Brain. 2021. ↩︎
Liu Y, et al. Targeting B cells in neurodegenerative disease therapy. Nat Rev Drug Discov. 2020. ↩︎